Amphastar Pharmaceuticals (AMPH) Scheduled to Post Quarterly Earnings on Wednesday

Amphastar Pharmaceuticals (NASDAQ:AMPH) will announce its earnings results after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of $0.73 per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, February 28th. The company reported $0.81 EPS for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.03). Amphastar Pharmaceuticals had a return on equity of 26.95% and a net margin of 21.34%. The company had revenue of $178.11 million for the quarter, compared to the consensus estimate of $174.90 million. On average, analysts expect Amphastar Pharmaceuticals to post $3 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Amphastar Pharmaceuticals Price Performance

NASDAQ:AMPH traded up $0.51 during mid-day trading on Monday, reaching $42.97. 18,005 shares of the company were exchanged, compared to its average volume of 440,280. Amphastar Pharmaceuticals has a 12 month low of $36.06 and a 12 month high of $67.66. The company has a fifty day moving average of $43.48 and a 200 day moving average of $50.78. The company has a quick ratio of 1.70, a current ratio of 2.17 and a debt-to-equity ratio of 0.92. The stock has a market cap of $2.07 billion, a PE ratio of 16.46, a PEG ratio of 1.02 and a beta of 0.85.

Analyst Ratings Changes

A number of equities research analysts have commented on AMPH shares. StockNews.com lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. JPMorgan Chase & Co. initiated coverage on shares of Amphastar Pharmaceuticals in a research report on Tuesday, March 5th. They set an “overweight” rating and a $60.00 target price on the stock. Finally, Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a research report on Wednesday, April 10th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $66.00.

Insider Activity at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff sold 12,500 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $47.18, for a total transaction of $589,750.00. Following the sale, the director now directly owns 21,326 shares in the company, valued at approximately $1,006,160.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 14,000 shares of company stock worth $655,145 in the last ninety days. Company insiders own 27.10% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.